Researchers and doctors at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research have discovered a potential explanation for why breast cancer is not experienced the same way with African American ...
Jun 2, 2012
0
0
Researchers at Kanazawa University report in Nature Communications that AXL, a protein belonging to the class of receptor tyrosine kinases, causes some lung cancer patients to have an intrinsic resistance to the drug osimertinib. ...
Feb 26, 2019
0
0
Adding trastuzumab (trade name Herceptin) to the treatment offered to women who have HER2-positive breast cancer, significantly increases the chance of life being prolonged, and reduces the chance of tumours reappearing once ...
Apr 17, 2012
0
0
(HealthDay)—A new drug to treat advanced lung cancer has been approved by the U.S. Food and Drug Administration.
Jul 12, 2013
0
0
Researchers have shown for the first time that a crucial interface in a protein that drives cancer growth could act as a target for more effective treatments.
Mar 19, 2024
0
47
More than a cancer-causing gene is needed to trigger pancreatic cancer, a study led by Mayo Clinic has found. A second factor creates a "perfect storm" that allows tumors to form, the researchers say. The study, published ...
Sep 10, 2012
0
3
Lung tumors called adenocarcinomas sometimes respond to initially effective treatments by transforming into a much more aggressive small cell lung cancer (SCLC) that spreads rapidly and has few options for treatment. Researchers ...
Feb 8, 2024
0
10
Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies. They found that bexarotene and erlotinib can each ...
Jun 2, 2011
0
0
(HealthDay)—Semiquantitative immunohistochemical expression of progesterone receptor-positive tumor cells improves prediction of survival within luminal A breast cancers, according to a study published online Dec. 10 in ...
Dec 17, 2012
0
0
Drugs introduced more than a decade ago that target mutations in a protein known as the epidermal growth factor receptor (EGFR) held the promise of personalized treatments for a common form of non-small cell lung cancer. ...
May 20, 2015
0
33
